Evidence map›Paper›PMID 29907806›Full record

Trial reportBone marrow transplantation2019

Final outcomes of escalated melphalan 280 mg/m

Parameswaran Hari, Donna E Reece, Jasleen Randhawa, Neal Flomenberg, Dianna S Howard, Ashrof Z Badros, Aaron P Rapoport, Barry R Meisenberg, Joanne Filicko-Ohara, Gordon L Phillips and 1 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Parameswaran HariMedical College of Wisconsin, Milwaukee, WI, USA.
Donna E ReecePrincess Margaret Hospital, Toronto, ON, Canada.
Jasleen RandhawaMedical College of Wisconsin, Milwaukee, WI, USA.
Neal FlomenbergThomas Jefferson University, Philadelphia, PA, USA.
Dianna S HowardWake Forest Baptist Medical Center Wake Forest, Winston-Salem, NC, USA.
Ashrof Z BadrosUniversity of Maryland, Baltimore, MD, USA.
Aaron P RapoportUniversity of Maryland, Baltimore, MD, USA.
Barry R MeisenbergDeCesaris Cancer Institute, Anne Arundel Medical Center, Annapolis, MD, USA.
Joanne Filicko-OharaThomas Jefferson University, Philadelphia, PA, USA.
Gordon L PhillipsWake Forest Baptist Medical Center Wake Forest, Winston-Salem, NC, USA.
David H VesoleJohn Theurer Cancer Center at Hackensack UMC, Hackensack, NJ, USA. david.vesole@hackensackmeridian.org.
Atrium Health Wake Forest Baptist · USMedical College of Wisconsin · USThomas Jefferson University · USUniversity of Maryland, Baltimore · USAnne Arundel Medical Center · USHackensack University Medical Center · USPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m

Indexed as

AdultAgedAmifostineCytoprotectionDisease-Free SurvivalDose-Response Relationship, DrugFemaleHematopoietic Stem Cell TransplantationHumansMaleMaximum Tolerated DoseMelphalanMiddle AgedMultiple MyelomaProspective StudiesRemission InductionAmifostineMelphalan

Identifiers

PMID29907806
OpenAlexW2808562501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.